Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor lysate-pulsed dendritic cell vaccine + resiquimod
- Development stage
- Unknown
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Intradermal, Topical
01
Overview
This investigational immunotherapy combination consists of an autologous dendritic cell (DC) vaccine pulsed with tumor lysate antigens, administered in conjunction with the Toll-like receptor (TLR) 7/8 agonist resiquimod. Developed by the Jonsson Comprehensive Cancer Center at UCLA, the vaccine is produced by isolating a patient's own dendritic cells and loading them with antigens derived from the patient's own tumor tissue (lysate). This process is designed to prime the immune system to recognize and attack specific intracranial tumor cells. Resiquimod is used as an adjuvant, typically applied topically at the vaccination site, to enhance the maturation of the dendritic cells and stimulate a robust T-cell-mediated anti-tumor response. The combination has been primarily evaluated in Phase II clinical trials for the treatment of malignant gliomas, including glioblastoma multiforme.
- Other names
- Tumor lysate-pulsed DC vaccination + 0.2% resiquimodDC vaccine + resiquimodAutologous tumor lysate-pulsed DC vaccination + resiquimod
02
Targets
TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on autologous tumor lysate-pulsed dendritic cell vaccine + resiquimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor lysate-pulsed dendritic cell vaccine + resiquimod.